Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2020 - 2025)
Summit Therapeutics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $42000.0 for Q4 2025.
- For Q4 2025, Depreciation & Amortization (CF) rose 90.91% year-over-year to $42000.0; the TTM value through Dec 2025 reached $146000.0, up 64.04%, while the annual FY2025 figure was $146000.0, 64.04% up from the prior year.
- Depreciation & Amortization (CF) reached $42000.0 in Q4 2025 per SMMT's latest filing, roughly flat from $42000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $99000.0 in Q2 2022 to a low of $20000.0 in Q2 2024.
- Average Depreciation & Amortization (CF) over 5 years is $55600.0, with a median of $44000.0 recorded in 2023.
- Peak YoY movement for Depreciation & Amortization (CF): surged 125.71% in 2021, then plummeted 70.0% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $79000.0 in 2021, then rose by 11.39% to $88000.0 in 2022, then crashed by 65.91% to $30000.0 in 2023, then decreased by 26.67% to $22000.0 in 2024, then soared by 90.91% to $42000.0 in 2025.
- Per Business Quant, the three most recent readings for SMMT's Depreciation & Amortization (CF) are $42000.0 (Q4 2025), $42000.0 (Q3 2025), and $37000.0 (Q2 2025).